QPPV.COM KNOWLEDGE ASSESSMENT

Vendor Audits in Pharmacovigilance: Knowledge Assessment

Test your understanding of the concepts covered by Vendor Audits in Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 During an inspection, which evidence package would most convincingly demonstrate control of a critical vendor issue?

The signed vendor contract alone A vendor marketing presentation and an unsigned meeting agenda A chronological record including containment, affected case assessment, RCA, implemented CAPA, reprocessing results, effectiveness verification and escalation records A statement that no complaints were received after the audit

Question 2 of 10 Which statement best captures the regulatory significance of a risk-based vendor audit programme?

Regulators expect identical audit scope and frequency for all vendors Risk-based planning supports a defensible demonstration that oversight resources and verification activities match the potential risk Risk-based planning permits the sponsor to exclude critical vendors from audits A risk assessment removes the need to retain audit records

Question 3 of 10 A low-risk vendor performs a limited administrative activity with no direct involvement in safety reporting. Which audit strategy is most consistent with the article's risk-based approach?

The same broad, annual on-site audit used for critical case-processing vendors No oversight because the vendor is low risk Limited audits, remote reviews or periodic assessments proportionate to the risk Immediate escalation of all observations to competent authorities

Question 4 of 10 Why should data protection constraints and secure evidence-transfer mechanisms be agreed before a remote audit?

To prevent auditors from reviewing any case information To ensure relevant evidence can be accessed lawfully and securely, with appropriate redaction and transfer controls To allow the vendor to select only favourable records To eliminate the need for confidentiality agreements

Question 5 of 10 A sponsor accepts a vendor's statement that a Major CAPA is complete but does not review implementation records or perform an effectiveness check. What is the principal governance weakness?

The sponsor has applied excessive independent verification The sponsor has treated completion as equivalent to effectiveness without objective evidence The sponsor has used a risk-based approach The sponsor has performed an unnecessary audit

Question 6 of 10 What is a key limitation of a remote vendor audit compared with an on-site audit?

Remote audits cannot review documents or conduct interviews Remote audits are always invalid for pharmacovigilance activities Remote audits may provide reduced visibility and fewer opportunities for direct observation Remote audits cannot assess contractual obligations

Question 7 of 10 What is the distinctive value of a vendor audit within a pharmacovigilance oversight framework?

It replaces the need for contracts and service-level agreements It provides independent verification that outsourced activities remain under control It guarantees that no future deviations will occur It transfers the sponsor's regulatory accountability to the vendor

Question 8 of 10 What is the principal difference between a symptom-focused CAPA and a strong CAPA?

A strong CAPA avoids documenting the underlying issue A symptom-focused CAPA is always faster and therefore preferable A strong CAPA addresses root causes and reduces the likelihood of recurrence A strong CAPA applies only to observations

Question 9 of 10 What is the most appropriate role of the QPPV in relation to vendor audits?

The QPPV must personally perform every vendor audit The QPPV has no role because the vendor is contractually responsible The QPPV should have appropriate visibility of serious findings, significant risks, high-risk vendors and escalated CAPAs The QPPV should approve all routine administrative observations personally

Question 10 of 10 Why is an evidence index linking each finding to supporting documents valuable during an inspection?

It allows the organisation to omit the finding description It improves traceability and enables inspectors to connect observations, risk assessments and remediation evidence efficiently It ensures that findings cannot be challenged by the vendor It replaces the need for a CAPA register

Vendor Audits in Pharmacovigilance: Knowledge Assessment

Cookie Settings